U.S. payers and CGP: Equip your lab for reimbursement of CGP with TSO Comprehensive
U.S. payers and CGP: Equip your lab for reimbursement of CGP with TSO Comprehensive
TruSight™ Oncology Comprehensive (TSO Comprehensive) is the first U.S. FDA-approved, distributable comprehensive genomic profiling (CGP) kit with pan-cancer companion diagnostic (CDx) claims, across solid malignant neoplasms, conveys a distinct clinical utility that payers appreciate.
This webinar will highlight how your lab can navigate TSO Comprehensive reimbursement by engaging with your payers, which tools to use and information to highlight during the billing processes. A regional laboratory serving a wide network across 7 states will share its experience navigating CGP RUO reimbursement, providing rapid access to CGP results for their oncologist through systematic lab-initiated testing and how TSO Comprehensive could positively impact their bottom line.
Learning objectives • Learn about TSO Comprehensive unique value proposition for U.S. payers • Equip your lab to engage with your payers to maximize reimbursement of your CGP • Review a US regional lab experience in optimizing CGP reimbursement and implementing laboratory-initiated CGP testing to better serve its oncologists and patients
Fill out the form to access content
By submitting this form, you agree to have your contact information passed along for the purpose of following up on your interests and in order to receive communications regarding Illumina products, services, and events. The data sent will be processed in Canada and provided to Illumina who will assume responsibility for processing and Opt-out and Information Removal. For more information, please read our Terms of Use, Privacy, Opt-out & Information Removal.
Subscribe To Our Newsletter
Join our email list to get the exclusive unpublished content right in your inbox.